narrative_review · 2008
Pramlintide, the synthetic analogue of amylin
Hoogwerf BJ · Diabetes, Metabolic Syndrome and Obesity
moderatePMID · 18561511Verified
Plain-English summary
Pramlintide slows gastric emptying, suppresses post-meal glucagon and increases satiety, producing modest glycaemic and weight effects.
Population
People with type 1 or insulin-treated type 2 diabetes
Intervention
Pramlintide used as an adjunct to insulin
Outcomes measured
Postprandial glucose|HbA1c|Weight|Adverse effects
Key findings
Supports clinical efficacy of pramlintide with nausea and hypoglycaemia-management considerations.
Limitations
Narrative review|Applies to licensed pramlintide rather than all amylin analogues|Adjunctive insulin contextRisk of bias
Moderate — established clinical literature, but narrative rather than systematic review.Citation
Hoogwerf BJ (2008). Pramlintide, the synthetic analogue of amylin. Diabetes, Metabolic Syndrome and Obesity
Linked peptides in the PeptiBrief database